VIRX Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (31 May 2024 @ 16:00):

Stats
Today's Volume	47 537.00
Average Volume	99 812.00
Market Cap	27.49M
EPS	$0 ( 2024-05-13 )
Next earnings date	( $-0.350 ) 2024-06-18
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.570
ATR14	$0.0150 (2.15%)

Insider Trading

Date	Person	Action	Amount	type
2024-05-25	Pomerantz Roger	Buy	9 035	Common Stock
2024-05-25	Pomerantz Roger	Sell	9 035	Restricted Stock Units
2024-05-25	Royston Ivor	Buy	25 219	Common Stock
2024-05-25	Royston Ivor	Sell	25 219	Restricted Stock Units
2024-05-14	Faerm Michael E.	Buy	500 000	Stock Option (Right to Buy)

INSIDER POWER
70.61
Last 96 transactions
Buy: 5 106 750 \| Sell: 640 278

Volume Correlation

Long: -0.04 (neutral)

Short: -0.39 (neutral)

Signal:(44.387) Neutral

Sunesis Pharmaceuticals Correlation

10 Most Positive Correlations
TRMB	0.918
PCAR	0.914
LNW	0.913
TRVI	0.913
PLYA	0.91
RTH	0.908
BLCN	0.906
ICLR	0.901
CFA	0.9
CFO	0.9

10 Most Negative Correlations
SABR	-0.901
IRDM	-0.877
SSRM	-0.87
CYAN	-0.856
WISA	-0.855
MFIN	-0.85
SSP	-0.849
GIGM	-0.845
DPRO	-0.84
INVA	-0.838

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Sunesis Pharmaceuticals Correlation - Currency/Commodity

-0.24
( neutral )

0.01
( neutral )

0.00
( neutral )

0.01
( neutral )

0.11
( neutral )

Sunesis Pharmaceuticals Financials

Annual	2023
Revenue:	$0
Gross Profit:	$-492 000 (0.00 %)
EPS:	$-1.320

FY	2023
Revenue:	$0
Gross Profit:	$-492 000 (0.00 %)
EPS:	$-1.320

FY	2022
Revenue:	$0
Gross Profit:	$-210 000 (0.00 %)
EPS:	$-1.320

FY	2021
Revenue:	$0.00
Gross Profit:	$0.00 (0.00 %)
EPS:	$0

Financial Reports:

No articles found.

Sunesis Pharmaceuticals Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Sunesis Pharmaceuticals

Viracta Therapeutics, Inc., a precision oncology company, engages in developing drugs for the treatment of virus-associated malignancies. Its lead product candidature includes Nana-val, in combination with nanatinostat and valganciclovir that is in Phase II clinical trial for Epstein-Barr virus-positive lymphoma; and open-label Phase 2 basket trial for the treatment of various relapsed/refractory Epstein-Barr virus-positive (EBV+) lymphoma, as well as an open-label Phase 1b/2 trial for the treatment of EBV+ recurrent or metastatic nasopharyngeal carcinoma and other EBV+ solid tumors. The company's development pipeline includes vecabrutinib, a clinical-stage non-covalent ITK/BTK inhibitor and VRx-510 (formerly SNS-510), a preclinical-stage PDK-1 inhibitor. It is evaluating development and collaboration opportunities for vecabrutinib in combination with chimeric antigen receptor T-cell therapies and VRx-510 in various oncology indications. The company was formerly known as Sunesis Pharmaceuticals, Inc. to Viracta Therapeutics, Inc. in February 25, 2021. Viracta Therapeutics, Inc. was incorporated in 1998 and is headquartered in Cardiff-by-the-Sea, California.